Reorganization of metastamiRs in the evolution of metastatic aggressive neuroblastoma cells

BMC Genomics

Volumn 16, Issue 1, 2015, Pages

  Khan, Faizan H ^a   Pandian, Vijayabaskar ^a   Ramraj, Satishkumar ^a   Aravindan, Sheeja ^b   Herman, Terence S ^a,b   Aravindan, Natarajan ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b Section of Gynecology Oncology Stephenson Cancer Center   (United States)

Author keywords

Aggressive metastatic cells; High risk metastatic disease; MetastamiRS; miRNA; Neuroblastoma; SH SY5Y; Tumor progression

Indexed keywords

ADAMTS1 PROTEIN; APOPTOSIS SIGNAL REGULATING KINASE 1; AURORA B KINASE; BETA CATENIN; CASPASE 8; CHEMOKINE RECEPTOR CXCR4; CONNECTIVE TISSUE GROWTH FACTOR; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; EPIDERMAL GROWTH FACTOR RECEPTOR; GELATINASE A; GLYCOGEN SYNTHASE KINASE 3BETA; GROWTH FACTOR RECEPTOR BOUND PROTEIN 10; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1ALPHA; K RAS PROTEIN; METASTAMIR; MICRORNA; MONOCYTE CHEMOTACTIC PROTEIN 1; MYC PROTEIN; NEURONAL APOPTOSIS INHIBITORY PROTEIN; PROTEIN C FOS; PROTEIN KINASE B; STROMELYSIN; TRANSCRIPTION FACTOR ELK 1; TRANSCRIPTION FACTOR FOSB; TRANSCRIPTION FACTOR JUND; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOINFORMATICS; CANCER PROGNOSIS; CHILD; CONTROLLED STUDY; DATA MINING; EX VIVO STUDY; FEMALE; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS; MOUSE; NEUROBLASTOMA CELL; NONHUMAN; OVERALL SURVIVAL; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE MICROARRAY; ANIMAL; BIOLOGY; DISEASE COURSE; DISEASE FREE SURVIVAL; GENE EXPRESSION REGULATION; GENETICS; MICROARRAY ANALYSIS; NEUROBLASTOMA; NUDE MOUSE; PATHOLOGY; PROCEDURES; PROGNOSIS; TUMOR CELL LINE; TUMOR RECURRENCE;

ANIMALS; CELL LINE, TUMOR; COMPUTATIONAL BIOLOGY; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICE, NUDE; MICROARRAY ANALYSIS; MICRORNAS; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEUROBLASTOMA; PROGNOSIS;

EID: 84934768325     PISSN: None     EISSN: 14712164     Source Type: Journal    
DOI: 10.1186/s12864-015-1642-x     Document Type: Article

References (62)

1. Marc TG, Gurney. JG, Smith. MA, Olshan. AF: Sympathetic Nervous System Tumors. Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975-1995, National Cancer Institute, Bethesda, MD 1999, NIH Pub. No. 99-4649(ICCC IV):65-72.
2. Gurney. JG, Smith. MA, Ross. JA: Cancer Among Infants. Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975-1995, National Cancer Institute, Bethesda, MD 1999, NIH Pub. No. 99-4649 (XII):149-156
3. Morgenstern DA, Baruchel S, Irwin MS. Current and future strategies for relapsed neuroblastoma: challenges on the road to precision therapy. J Pediatr Hematol Oncol. 2013;35(5):337-47.
4. American-Cancer-Society.: Cancer Facts & Figures Atlanta: American Cancer Society 2015:1-56
5. Smith MA, Seibel NL, Altekruse SF, Ries LA, Melbert DL, O'Leary M, et al. Outcomes for children and adolescents with cancer: challenges for the twenty-first century. J Clin Oncol. 2010;28(15):2625-34.
6. Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet. 2007;369(9579):2106-20.
7. Matthay KK, Reynolds CP, Seeger RC, Shimada H, Adkins ES, Haas-Kogan D, et al. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study. J Clin Oncol. 2009;27(7):1007-13.
8. Cole KA, Maris JM. New strategies in refractory and recurrent neuroblastoma: translational opportunities to impact patient outcome. Clin Cancer Res. 2012;18(9):2423-8.
9. Santana VM, Furman WL, McGregor LM, Billups CA. Disease control intervals in high-risk neuroblastoma. Cancer. 2008;112(12):2796-801.
10. Simon T, Berthold F, Borkhardt A, Kremens B, De Carolis B, Hero B. Treatment and outcomes of patients with relapsed, high-risk neuroblastoma: results of German trials. Pediatr Blood Cancer. 2011;56(4):578-83.
11. Lau L, Tai D, Weitzman S, Grant R, Baruchel S, Malkin D. Factors influencing survival in children with recurrent neuroblastoma. J Pediatr Hematol Oncol. 2004;26(4):227-32.
12. Berthold F, Hero B, Breu H, Christiansen H, Erttmann R, Gnekow A, et al. The recurrence patterns of stages I, II and III neuroblastoma: experience with 77 relapsing patients. Ann Oncol. 1996;7(2):183-7.
13. Garaventa A, Parodi S, De Bernardi B, Dau D, Manzitti C, Conte M, et al. Outcome of children with neuroblastoma after progression or relapse A retrospective study of the Italian neuroblastoma registry. Eur J Cancer. 2009;45(16):2835-42.
14. Weiss B, Vora A, Huberty J, Hawkins RA, Matthay KK. Secondary myelodysplastic syndrome and leukemia following 131I-metaiodobenzylguanidine therapy for relapsed neuroblastoma. J Pediatr Hematol Oncol. 2003;25(7):543-7.
15. London WB, Castel V, Monclair T, Ambros PF, Pearson AD, Cohn SL, et al. Clinical and biologic features predictive of survival after relapse of neuroblastoma: a report from the International Neuroblastoma Risk Group project. J Clin Oncol. 2011;29(24):3286-92.
16. Christofori G. New signals from the invasive front. Nature. 2006;441(7092):444-50.
17. Gupta GP, Massague J. Cancer metastasis: building a framework. Cell. 2006;127(4):679-95.
18. Schmidt-Kittler O, Ragg T, Daskalakis A, Granzow M, Ahr A, Blankenstein TJ, et al. From latent disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progression. Proc Natl Acad Sci U S A. 2003;100(13):7737-42.
19. Kratimenos P, Koutroulis I, Marconi D, Syriopoulou V, Delivoria-Papadopoulos M, Chrousos GP, Theocharis S: Multi-targeted molecular therapeutic approach in aggressive neuroblastoma: the effect of Focal Adhesion Kinase-Src-Paxillin system. Expert opinion on therapeutic targets 2014;18(12):1395-406
20. Li Y, Li W, Zhang JG, Li HY, Li YM: Downregulation of tumor suppressor menin by miR-421 promotes proliferation and migration of neuroblastoma. Tumour biology. 2014;35(10):10011-7.
21. Morgenstern DA, London WB, Stephens D, Volchenboum SL, Hero B, Di Cataldo A, et al. Metastatic neuroblastoma confined to distant lymph nodes (stage 4 N) predicts outcome in patients with stage 4 disease: A study from the International Neuroblastoma Risk Group Database. J Clin Oncol. 2014;32(12):1228-35.
22. Cheng L, Yang T, Kuang Y, Kong B, Yu S, Shu H, et al. MicroRNA-23a promotes neuroblastoma cell metastasis by targeting CDH1. Oncology letters. 2014;7(3):839-45.
23. Li Y, Wang H, Li J, Yue W. MiR-181c modulates the proliferation, migration, and invasion of neuroblastoma cells by targeting Smad7. Acta Biochim Biophys Sin. 2014;46(1):48-55.
24. Hurst DR, Edmonds MD, Welch DR. Metastamir: the field of metastasis-regulatory microRNA is spreading. Cancer Res. 2009;69(19):7495-8.
25. Bell E, Chen L, Liu T, Marshall GM, Lunec J, Tweddle DA. MYCN oncoprotein targets and their therapeutic potential. Cancer Lett. 2010;293(2):144-57.
26. Maris JM. Recent advances in neuroblastoma. N Engl J Med. 2010;362(23):2202-11.
27. Seeger RC, Brodeur GM, Sather H, Dalton A, Siegel SE, Wong KY, et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med. 1985;313(18):1111-6.
28. Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science. 1984;224(4653):1121-4.
29. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer. 2003;3(3):203-16.
30. Brodeur GM, Bagatell R. Mechanisms of neuroblastoma regression. Nat Rev Clin Oncol. 2014;11(12):704-13.
31. Molenaar JJ, Koster J, Zwijnenburg DA, van Sluis P, Valentijn LJ, van der Ploeg I, et al. Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes. Nature. 2012;483(7391):589-93.
32. Hogarty MD, Maris JM. PI3King on MYCN to improve neuroblastoma therapeutics. Cancer Cell. 2012;21(2):145-7.
33. Cohn SL, Tweddle DA. MYCN amplification remains prognostically strong 20 years after its "clinical debut". Eur J Cancer. 2004;40(18):2639-42.
34. Kawa K, Ohnuma N, Kaneko M, Yamamoto K, Etoh T, Mugishima H, et al. Long-term survivors of advanced neuroblastoma with MYCN amplification: A report of 19 patients surviving disease-free for more than 66 months. J Clin Oncol. 1999;17(10):3216-20.
35. Cohn SL, London WB, Huang D, Katzenstein HM, Salwen HR, Reinhart T, et al. MYCN expression is not prognostic of adverse outcome in advanced-stage neuroblastoma with nonamplified MYCN. J Clin Oncol. 2000;18(21):3604-13.
36. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281-97.
37. Bottai G, Pasculli B, Calin GA, Santarpia L: Targeting the microRNA-regulating DNA damage/repair pathways in cancer. Expert opin biol ther 2014;14(11):1667-83
38. Chen Y, Liu XR, Yin YQ, Lee CJ, Wang FT, Liu HQ, et al. Unravelling the multifaceted roles of Atg proteins to improve cancer therapy. Cell Prolif. 2014;47(2):105-12.
39. Fu J, Xu X, Kang L, Zhou L, Wang S, Lu J, et al. Biochem Biophys Res Commun. 2014;445(2):314-9.
40. Elzein S, Goodyer CG. Regulation of Human Growth Hormone Receptor Expression by MicroRNAs. Mol Endocrinol. 2014;28(9):1448-59.
41. Liu F, Lv Q, Du WW, Li H, Yang X, Liu D, et al. Specificity of miR-378a-5p targeting rodent fibronectin. Biochim Biophys Acta. 2013;1833(12):3272-85.
42. Kim VN. MicroRNA biogenesis: coordinated cropping and dicing. Nat Rev Mol Cell Biol. 2005;6(5):376-85.
43. Cheung IY, Farazi TA, Ostrovnaya I, Xu H, Tran H, Mihailovic A, et al. Deep MicroRNA sequencing reveals downregulation of miR-29a in neuroblastoma central nervous system metastasis. Genes Chromosomes Cancer. 2014;53(10):803-14.
44. Gonzalez-Nunez V, Noriega-Prieto JA, Rodriguez RE. Morphine modulates cell proliferation through mir133b &mir128 in the neuroblastoma SH-SY5Y cell line. Biochim Biophys Acta. 2014;1842(4):566-72.
45. Chen X, Pan M, Han L, Lu H, Hao X, Dong Q. miR-338-3p suppresses neuroblastoma proliferation, invasion and migration through targeting PREX2a. FEBS Lett. 2013;587(22):3729-37.
46. Qiao J, Lee S, Paul P, Theiss L, Tiao J, Qiao L, et al. miR-335 and miR-363 regulation of neuroblastoma tumorigenesis and metastasis. Surgery. 2013;154(2):226-33.
47. Ye J, Wu X, Wu D, Wu P, Ni C, Zhang Z, et al. miRNA-27b targets vascular endothelial growth factor C to inhibit tumor progression and angiogenesis in colorectal cancer. PLoS One. 2013;8(4):e60687.
48. Zhang H, Pu J, Qi T, Qi M, Yang C, Li S, et al. MicroRNA-145 inhibits the growth, invasion, metastasis and angiogenesis of neuroblastoma cells through targeting hypoxia-inducible factor 2 alpha. Oncogene. 2014;33(3):387-97.
49. Xin C, Buhe B, Hongting L, Chuanmin Y, Xiwei H, Hong Z, et al. MicroRNA-15a promotes neuroblastoma migration by targeting reversion-inducing cysteine-rich protein with Kazal motifs (RECK) and regulating matrix metalloproteinase-9 expression. FEBS J. 2013;280(3):855-66.
50. Zhang H, Qi M, Li S, Qi T, Mei H, Huang K, et al. microRNA-9 targets matrix metalloproteinase 14 to inhibit invasion, metastasis, and angiogenesis of neuroblastoma cells. Mol Cancer Ther. 2012;11(7):1454-66.
51. Meseguer S, Mudduluru G, Escamilla JM, Allgayer H, Barettino D. MicroRNAs-10a and -10b contribute to retinoic acid-induced differentiation of neuroblastoma cells and target the alternative splicing regulatory factor SFRS1 (SF2/ASF). J Biol Chem. 2011;286(6):4150-64.
52. Kovalevich J, Langford D. Considerations for the use of SH-SY5Y neuroblastoma cells in neurobiology. Methods Mol Biol. 2013;1078:9-21.
53. Aravindan S, Natarajan M, Awasthi V, Herman TS, Aravindan N. Novel synthetic monoketone transmute radiation-triggered NFkappaB-dependent TNFalpha cross-signaling feedback maintained NFkappaB and favors neuroblastoma regression. PLoS One. 2013;8(8):e72464.
54. Veeraraghavan J, Natarajan M, Aravindan S, Herman TS, Aravindan N. Radiation-triggered tumor necrosis factor (TNF) alpha-NFkappaB cross-signaling favors survival advantage in human neuroblastoma cells. J Biol Chem. 2011;286(24):21588-600.
55. Chen X, Zhu Y, Han L, Lu H, Hao X, Dong Q. Chemokine receptor 4 gene silencing blocks neuroblastoma metastasis in vitro. Neural Regeneration Res. 2014;9(10):1063-7.
56. Tian X, Hou W, Bai S, Fan J, Tong H, Xu H. XAV939 inhibits the stemness and migration of neuroblastoma cancer stem cells via repression of tankyrase 1. Int J Oncol. 2014;45(1):121-8.
57. Feduska JM, Aller SG, Garcia PL, Cramer SL, Council LN, van Waardenburg RC, Yoon KJ: ICAM-2 confers a non-metastatic phenotype in neuroblastoma cells by interaction with alpha-actinin. Oncogene 2015;34(12):1553-62.
58. Schwankhaus N, Gathmann C, Wicklein D, Riecken K, Schumacher U, Valentiner U: Cell adhesion molecules in metastatic neuroblastoma models. Clinical & experimental metastasis 2014;31(4):483-496.
59. Guo J, Dong Q, Fang Z, Chen X, Lu H, Wang K, et al. Identification of miRNAs that are associated with tumor metastasis in neuroblastoma. Cancer Biol Ther. 2010;9(6):446-52.
60. Almeida MI, Reis RM, Calin GA. MicroRNAs and metastases-the neuroblastoma link. Cancer Biol Ther. 2010;9(6):453-4.
61. Khew-Goodall Y, Goodall GJ. Myc-modulated miR-9 makes more metastases. Nat Cell Biol. 2010;12(3):209-11.
62. Natarajan M, Aravindan N, Meltz ML, Herman TS. Post-translational modification of I-kappa B alpha activates NF-kappa B in human monocytes exposed to 56Fe ions. Radiat Environ Biophys. 2002;41(2):139-44.